The life science investment firm Bioluminescence Ventures will close its doors less than two years after its founding, ...

The Mitsubishi Chemical Group is selling its centuries-old pharmaceutical business to Bain Capital in a carve-out worth about ...

Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech found success with a different B cell-killing ...

Acelyrin merges with Alumis in all-stock deal, transferring $448M cash and lonigutamab asset. Martin Babler to lead combined ...

B Health and two hospitals seek to intervene in Eli Lilly lawsuit, saying proposed rebate model would burden hospitals with ...

Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...

Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans for regulatory filing this year.

Cystic fibrosis biotech Sionna Therapeutics will raise $191 million in its upsized Nasdaq debut on Friday, and metabolic disease biotech Aardvark Therapeutics outlined plans for a potential $89 ...

After promoting its oncology officer Chris Boshoff to chief scientific officer last fall, Pfizer has found his successor.

It took one month for Johnson & Johnson to secure its $14 billion acquisition of Intra-Cellular Therapies, according to new ...

AstraZeneca cuts UK investment after government reduces site expansion support; Viking secures API supply; Jabil acquires ...

AstraZeneca on Thursday provided insight on an ongoing China probe into the company concerning alleged illegal drug imports, ...